Skip to main content

Locus Biosciences Lifts Lid on Crafty CRISPR to Bust Bad Bacteria

Raleigh bioscience startup Locus Biosciences, a spinout of North Carolina State University, is using a version of the hot gene-editing technology called CRISPR to cut a new path to the discovery and development of novel antibiotics.

Inside View: A Kind Gentleman and Nobel Laureate

It was a gray afternoon in March, 2008 at the North Carolina Biotechnology Center. A kindly looking gentleman stood in our Congressional Room, surrounded by a group of North Carolina’s brightest young scientists, winners of various science competitions across the state that year.

UNC Nobel Laureate Oliver Smithies Dead at 91

Oliver Smithies, D.Phil., who was recruited to North Carolina with grant funding from the North Carolina Biotechnology Center and won the Nobel Prize in Physiology or Medicine 20 years later, died today at the age of 91.

New G1 Trials Target Breast Cancer

G1 Therapeutics, a clinical-stage oncology company based in Research Triangle Park, is expanding its search for new anti-cancer weapons by launching three more clinical trials targeting breast cancer.

Durham's GeneCentric Gets Bristol-Myers Squibb Buy-In

Durham’s GeneCentric Diagnostics has received an undisclosed sum of equity funding for a biomarker research collaboration with pharmaceutical giant Bristol-Myers Squibb.

Viamet Reports Positive Clinical Results for Anti-fungal Compound

Durham-based Viamet Pharmaceuticals has reported positive results from clinical trials of its lead product candidate for the treatment of two common fungal infections.

Cohera Medical Begins Clinical Trial of Surgical Sealant

Cohera Medical Inc., a medical-device company that relocated to Raleigh from Pittsburgh a year ago, has enrolled the first patient in a clinical trial of its Sylys Surgical Sealant.

Humacyte Starts Phase 2 Trial of Bioengineered Blood Vessel

Humacyte, a regenerative medicine company based in Morrisville, has launched a Phase 2 clinical trial of Humacyl, its bioengineered blood vessel, in patients with peripheral arterial disease.

RAUMEDIC Nears First Anniversary at Western NC Factory

RAUMEDIC, a family-owned German company, is nearing its first anniversary at its $27 million development and production facility in western North Carolina.

FDA OK Positions RTP’s curasan Inc. for Growth

Research Triangle Park–based curasan Inc. is poised for growth in 2017, thanks to an important December 2016 milestone for its synthetic bone regeneration material CERASORB Ortho FOAM.

Pages

Subscribe to RSS - Human Health